Drug class
Preferential phosphodiesterase 4B (PDE4B) inhibitor; antifibrotic and immunomodulatory small molecule
Mechanism of action
Inhibits PDE4, with at least nine-fold preferential inhibition of PDE4B over PDE4A, PDE4C and PDE4D in vitro. This increases intracellular cAMP and reduces expression of profibrotic growth factors and inflammatory cytokines implicated in pulmonary fibrosis.
General use cases
- Treatment of idiopathic pulmonary fibrosis (IPF) in adults
- Treatment of progressive pulmonary fibrosis (PPF) in adults under the US product indication; it is not an acute bronchodilator or treatment for acute exacerbations
For general informational purposes only. Do not rely on, cross-reference, cite or use this information as evidence or support for legal, regulatory, commercial or other claims.
